KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Hematology / 2020 / Cilt: 37 - Sayı: 2

Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study

Bortezomib Temelli Tedavi Rejimleri Birincil veya İkincil Plazma Hücreli Lösemi Hastalarının Sonuçlarını İyileştirir: Retrospektif Kohort Çalışması

Huijuan WANG
Huixing ZHOU
Zhiyao ZHANG
Chuanying GENG
Wenming CHEN
Sayfa
91–97
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

For pPCLpatients, BBR predicted OS (p=0.029, HR=0.056, 95% CI=0.004-0.745)instead of ≥VGPR (p=0.272, HR=3.365, 95% CI=0.38-29.303).Conclusion: It was found that BBRs could significantly improve OS forboth pPCL and sPCL patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The management experience for plasma cell leukemia(PCL) is still limited by PCL’s rare incidence and aggressive course.
📊
Temel Bulgular & Veri:Thegoal of this study was to further identify the efficacy of bortezomibcontaining regimens for PCL in Chinese patients.Materials and Methods: In this study, 56 consecutive PCL patients[14 primary PCL (pPCL) and 42 secondary PCL (sPCL) cases] wereretrospectively enrolled and 42/56 patients received bortezomibbased regimens (BBRs), including 10/14 pPCL and 32/42 sPCL patients.The patients’ survival data, clinical information, and safety data werecollected and analyzed.Results: In pPCL and sPCL patients, the overall response rate in thebortezomib group was 90.0% and 25.0%, respectively.
💡
Sonuç & Katkı:For pPCLpatients, BBR predicted OS (p=0.029, HR=0.056, 95% CI=0.004-0.745)instead of ≥VGPR (p=0.272, HR=3.365, 95% CI=0.38-29.303).Conclusion: It was found that BBRs could significantly improve OS forboth pPCL and sPCL patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The management experience for plasma cell leukemia(PCL) is still limited by PCL’s rare incidence and aggressive course. Thegoal of this study was to further identify the efficacy of bortezomibcontaining regimens for PCL in Chinese patients.Materials and Methods: In this study, 56 consecutive PCL patients[14 primary PCL (pPCL) and 42 secondary PCL (sPCL) cases] wereretrospectively enrolled and 42/56 patients received bortezomibbased regimens (BBRs), including 10/14 pPCL and 32/42 sPCL patients.The patients’ survival data, clinical information, and safety data werecollected and analyzed.Results: In pPCL and sPCL patients, the overall response rate in thebortezomib group was 90.0% and 25.0%, respectively. The medianprogression-free survival from PCL diagnosis for pPCL and sPCL was8.3 months vs. 2.9 months (p=0.043) and median overall survival(OS) from PCL diagnosis was 23.3 months vs. 4.0 months. The OS forpatients receiving BBRs was significantly longer for both pPCL (8.3vs. 1.2 months, p=0.002) and sPCL (4.3 vs. 1.1 months, p<0.001). Inmultivariate COX analysis, BBR treatment [p=0.008, hazard ratio(HR)=0.38, 95% confidence interval (CI)=0.19-0.77] and very goodpartial response or better (≥VGPR) (p=0.035, HR=0.19, 95% CI=0.04-0.74) were independent predictors of OS for sPCL patients. For pPCLpatients, BBR predicted OS (p=0.029, HR=0.056, 95% CI=0.004-0.745)instead of ≥VGPR (p=0.272, HR=3.365, 95% CI=0.38-29.303).Conclusion: It was found that BBRs could significantly improve OS forboth pPCL and sPCL patients.

Abstract

Amaç: Plazma hücreli lösemide (PHL) tedavi deneyimi PHL’nin nadir görülmesi ve agresif seyri nedeni ile halen sınırlıdır. Bu çalışmanın amacı Çin’deki PHL hastalarında bortezomib temelli tedavi rejimlerinin etkinliğini belirlemektir. Gereç ve Yöntemler: Bu çalışmaya geriye dönük olarak 56 PHL olgusu [14 birincil PHL (pPHL) ve 42 ikincil PHL (sPHL)] dahil edilmiştir ve pPHL 10/14 ve sPHL 32/42 olmak üzere 42/56 olgu bortezomib temelli tedavi (BTT) almıştır. Hastaların sağ-kalım verileri, klinik bilgileri ve güvenlik verileri toplandı ve analiz edildi. Bulgular: PPHL ve sPHL hastalarında bortezomib grubunda genel yanıt oranı sırasıyla %90 ve %25 idi. PHL tanısından itibaren ortanca hastalıksız sağ kalım pPHL ve sPHL için sırasıyla 8,3 ay ve 2,9 ay (p=0,043) ve genel ortanca sağkalım (GS) 23,3 ay ve 4 ay idi. BTT alan hastalar için GS hem pPHL (8,3 aya 1,2 ay, p=0,002) hem de sPHL (4,3 aya 1,1 ay, p<0,001) için anlamlı olarak daha uzun bulundu. Çok değişkenli COX analizinde BTT [p=0,008, kalp atım oranı (KAO)=0,38, %95 güven aralığı (CI)=0.19-0.77] ve daha iyi ya da çok iyi kısmi yanıt (≥ÇİKY) (p=0,035, KAO=0,19, %95 CI=0,04-0,74), sPHL hastaları için GS’ın bağımsız göstergesidir. PPHL hastalarında BTT için öngörülen GS (p=0.029, KAO=0,056, %95 CI=0,004-0,745) iken, ≥ÇİKY için (p=0,272, HR=3,365, %95 CI=0,38-29,303) idi. Sonuç: BTT’nin hem pPHL hem de sPHL hastalarında genel sağkalımı belirgin olarak iyileştirebileceği bulunmuştur.

🔖

Bu Makaleye Atıf Yap

WANG, H., ZHOU, H., ZHANG, Z., GENG, C., CHEN, W. (2020). Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study. Turkish Journal of Hematology, Cilt: 37 - Sayı: 2, 91–97. https://ajindex.com/articles/411691

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-1052
  2. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974;133:813-818
  3. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83:1062-1068
  4. Mina R, D’Agostino M, Cerrato C, Gay F, Palumbo A. Plasma cell leukemia: update on biology and therapy. Leuk Lymphoma 2017;58:1538-1547
  5. D’Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, Musto P. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012;23:1499-1502
  6. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, Dimopoulos MA. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek Myeloma Study Group. Am J Hematol 2014;89:145-150
  7. Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myelome. J Clin Oncol 2016;34:2125-2132
  8. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D’Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omede P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide